Table 2.

Prognostic value of LBP with different clinicopathological factors in the LIHC cohort of TCGA from Kaplan-Meier plotter database.

		OS (n = 364)			RFS (n = 316)
		Patient number	P-value	HR [95% CI]	Patient number	P-value	HR [95% CI]
Pathology
Stage
	1 + 2	253	0.0062	3.2 (1.33–7.69)	227	0.4262	1.2 (0.77–1.88)
	3 + 4	87	0.0573	0.56 (0.31–1.03)	68
Grade
	1	55			45
	2	174	0.0981	1.57 (0.92–2.68)	147	0.3715	1.25 (0.77–2.03)
	3	118	0.104	1.65 (0.9–3.02)	106	0.1012	0.63 (0.37–1.1)
	4	12
AJCC_T
	1	180	0.024	1.97 (1.08–3.58)	160	0.3479	1.31 (0.75–2.29)
	2	90	0.0288	0.44 (0.21–0.94)	79
	3	78			65
	4	13			6
Vascular invasion
	None	203	0.1673	1.43 (0.86–2.4)	175	0.1106	1.49 (0.91–2.45)
	Micro	90	0.0451	2.37 (0.99–5.64)	81	0.3381	0.72 (0.36–1.42)
	Macro	16			14
Patient
Gender
	Male	246	0.124	1.42 (0.91–2.21)	208	0.044	0.64 (0.41–0.99)
	Female	118	0.0925	0.6 (0.33–1.09)	105	0.2189	1.47 (0.79–2.75)
Race
	White	181	0.216	0.72 (0.43–1.21)	147	0.1142	0.67 (0.41–1.1)
	Black or African American	17			13
	Asian	155	0.0508	1.83 (0.99–3.38)	143	0.1677	0.69 (0.4–1.17)
Sorafenib treatment
	Treated	30			22
Risk factors
Alcohol consumption
	Yes	115	0.1001	0.57 (0.29–1.12)	98	0.1184	0.61 (0.32–1.14)
	No	202	0.0332	1.65 (1.04–2.62)	183	0.2877	0.77 (0.47–1.25)
Hepatitis virus
	Yes	150	0.005	2.45 (1.28–4.67)	138	0.2678	0.74 (0.44–1.26)
	No	167	0.0066	0.52 (0.32–0.84)	143	0.1187	0.66 (0.39–1.12)

Cohorts patients only more than 80 were analyzed further.